Business Context and Reporting Period
Company: Incyte Genomics, Inc. (formerly Incyte Pharmaceuticals, Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2001
Business Overview: Incyte designs, develops, and markets genomic information-based products and services, including database products, microarray-based gene expression services, and genomic reagents. The company serves pharmaceutical and biotechnology companies and academic researchers. In December 2000, Incyte acquired Proteome, Inc., a proteomics information company, to expand its database offerings.
Key Financial Metrics
| Metric (in thousands) | Q1 2001 | Q1 2000 |
|---|---|---|
| Revenues | $51,121 | $40,754 |
| Total Costs and Expenses | $72,520 | $56,155 |
| Loss from Operations | $(21,399) | $(15,401) |
| Net Loss | $(10,312) | $(8,177) |
| Net Loss Per Share (Basic & Diluted) | $(0.16) | $(0.13) |
| Cash and Cash Equivalents (End of Period) | $114,689 | $421,334 |
| Marketable Securities | $452,651 | N/A |
| Total Current Assets | $609,853 | N/A |
| Convertible Subordinated Notes (Debt) | $179,580 | N/A |
| Accumulated Deficit | $(95,216) | N/A |
Liquidity: As of March 31, 2001, the company held $567.3 million in cash, cash equivalents, and marketable securities. Net cash provided by operating activities was $3.9 million for the quarter.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 25% to $51.1 million, driven by expanded customer base, partner programs, and increased custom genomics services.
- Expense Increase: Total costs and expenses rose 29% to $72.5 million. Research and Development (R&D) expenses increased to $56.0 million due to bioinformatics efforts, SNP discovery, and amortization related to the Proteome acquisition. Selling, General, and Administrative (SG&A) expenses rose to $16.6 million, partly due to legal fees ($1.9 million) associated with patent litigation.
- Net Loss Expansion: Net loss increased to $10.3 million from $8.2 million. However, this figure includes a $2.4 million extraordinary gain from debt repurchases and a $2.3 million gain from the cumulative effect of an accounting change (SFAS 133). Loss before these items was $15.0 million.
- Debt Reduction: The company repurchased $8.0 million in face value of its convertible subordinated notes during the quarter, recognizing a gain.
- Investing Activities: Net cash provided by investing activities was $5.4 million, primarily due to sales and maturities of marketable securities offset by purchases and capital expenditures.
Guidance, Outlook, and Risks
Outlook: Management expects to report a net loss at least through 2001 due to significant investments in internal disease pathway and therapeutic drug discovery programs, intellectual property portfolio development, and sequencing efforts. The company believes existing resources are adequate for at least the next twelve months.
Material Risks and Contingencies:
- Patent Litigation: Incyte is engaged in significant patent litigation with Affymetrix, Inc. regarding microarray technologies. While the court granted summary judgment in Incyte's favor on certain claims in May 2001, other claims remain pending. The company cannot estimate potential losses, but litigation costs are substantial and divert management attention.
- Profitability: The company has an accumulated deficit of $95.2 million and expects to incur losses in the future until revenues increase or expenses are reduced.
- Customer Concentration: Revenue depends heavily on database collaborators. Loss of a major subscriber could materially impact results.
- Acquisition Integration: Risks associated with integrating the recently acquired Proteome, Inc. operations and technology.
- Market Risks: Exposure to interest rate risk on marketable securities and foreign exchange rate fluctuations, though management does not expect these to be material.
Investor Verification Checklist
- Debt Obligations: Verify the terms and conversion price ($67.42) of the $179.6 million in convertible subordinated notes due in 2007.
- Litigation Status: Monitor the ongoing Affymetrix litigation, specifically the status of counterclaims and the potential for injunctions or damages despite the recent summary judgment win.
- Burn Rate vs. Cash: Assess the sustainability of the current cash position ($567.3 million) against the projected increase in R&D and SG&A expenses.
- Revenue Quality: Analyze the mix of recurring database fees versus one-time custom service fees to gauge revenue stability.
- Proteome Integration: Evaluate the progress of integrating Proteome's proteomics database and the associated amortization impact on future earnings.